Clinical trial · Observational
Lean Body Mass and Side Effects in Patients With Lymphoma
The Relation Between Lean Body Mass and Side Effects Induced by Chemotherapy in Patients With Lymphoma: A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma. Secondarily, the maximum tolerable dose of chemotherapeutics (MTD), patients' quality of life (QOL), nutritional status and physical activity during the course of treatment are estimated.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Lymphoma | Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Malignant lymphoma patients
- description
- Identification of the patients who are/are not dose-reduced due to chemotherapy, and then look at the body composition in connection with this.
Primary outcomes (1)
- measure
- Lean Body Mass (LBM)
- timeFrame
- 8 weeks (two treatment cycles)
- description
- LBM measured by bioelectrical impedans corelated to the dosis of chemotherapeutics given
Secondary outcomes (4)
- measure
- Maximal tolerable dose of chemotherapeutics (microg/ml/kg LBM),
- timeFrame
- 8 weeks (two treatment cycles)
- description
- Patients with side effects - correlation between dose of cytostatics/ kg LBM compared to patients without side effects
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients receiving myelosuppressive treatment for malignant lymphoma assessed by the investigator. * Legal of age Exclusion Criteria: * ECOG Performance Status ≥2 * People who cannot speak and understand Danish * Pregnant and breastfeeding * Dementia
References
Publications (0)
Data not yet available